Fortress Biotech, Inc. (FBIO): Price and Financial Metrics
FBIO Price/Volume Stats
| Current price | $1.82 | 52-week high | $12.60 |
| Prev. close | $1.80 | 52-week low | $1.24 |
| Day low | $1.72 | Volume | 336,200 |
| Day high | $1.84 | Avg. volume | 414,215 |
| 50-day MA | $1.92 | Dividend yield | N/A |
| 200-day MA | $3.79 | Market Cap | 35.01M |
FBIO Stock Price Chart Interactive Chart >
Fortress Biotech, Inc. (FBIO) Company Bio
Fortress Biotech, Inc., a biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. The company was founded in 2006 and is based in New York, New York.
Latest FBIO News From Around the Web
Below are the latest news stories about FORTRESS BIOTECH INC that investors may wish to consider to help them evaluate FBIO as an investment opportunity.
Analysts Expect Breakeven For Fortress Biotech, Inc. (NASDAQ:FBIO) Before LongWe feel now is a pretty good time to analyse Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) business as it appears the... |
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual MeetingData showed favorable safety profile, complete response rate and durability in the treatment of patients with relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma 100% of patients with follicular lymphoma achieved a complete response; no occurrence of CRS above grade 1 and no ICANS of any grade Complete responses observed in patients previously treated with CD19-targeted CAR T-cell therapy Outpatient administration found to be feasible WORCESTER, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- M |
Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.Cyprium received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales milestones Cyprium will retain 100% ownership over any FDA priority review voucher that may be issued at NDA approval for CUTX-101 MIAMI, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company, today announced that it executed an Assignment and Assumption Ag |
Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium TherapeuticsSentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (Zydus Group), today announced the execution of an Assignment and Assumption Agreement with Cyprium Therapeutics, Inc. (Cyprium), a Fortress Biotech, Inc. (Nasdaq: FBIO) (Fortress) subsidiary company. Under the agreement, Cyprium completed the transfer of its worldwide proprietary rights and U.S. FDA documents pertaining to CUTX-101, the copper histidinate product candidate for t |
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat RosaceaOn track to submit a New Drug Application to the FDA for DFD-29 around year-end of 2023SCOTTSDALE, Ariz., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company received the |
FBIO Price Returns
| 1-mo | -5.94% |
| 3-mo | -3.19% |
| 6-mo | -10.34% |
| 1-year | -84.91% |
| 3-year | -97.06% |
| 5-year | -92.51% |
| YTD | -39.53% |
| 2023 | -69.36% |
| 2022 | -73.80% |
| 2021 | -21.14% |
| 2020 | 23.35% |
| 2019 | 198.84% |
Continue Researching FBIO
Here are a few links from around the web to help you further your research on Fortress Biotech Inc's stock as an investment opportunity:Fortress Biotech Inc (FBIO) Stock Price | Nasdaq
Fortress Biotech Inc (FBIO) Stock Quote, History and News - Yahoo Finance
Fortress Biotech Inc (FBIO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...